On November 7, 2024 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, reported the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen (Grifols), Merus, Soleil, ThirdArc and Incyte, employing Vaccinex’s ActivMAb technology to generate antibodies to complex antigen targets (Press release, Vaccinex, NOV 7, 2024, View Source [SID1234647901]). In addition, Vaccinex has signed agreements to provide Charles River Labs, OmniAb, Adimab and other undisclosed strategic partners with materials to facilitate their antibody discovery programs using transgenic animal species for immunization or very large synthetic antibody libraries. The financial terms of the agreements are undisclosed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Vaccinex’s proprietary ActivMAb Technology enables expression of functional, properly folded complex proteins such as GPCRs and Ion Channels on the relatively simple membrane of poxvirus providing a source of antigen for various antibody discovery strategies. These strategies may involve development of antibody and antibody-based immunotherapies including bi-specifics, antibody drug conjugates (ADC), CAR-T cells, T cell engagers, etc. "Our technology is a powerful component of antibody discovery strategies targeting complex membrane proteins and enables both our own R&D efforts and those of our partners," said Ernest Smith, Chief Scientific Officer of Vaccinex. "These agreements and partnerships with established companies underscore ActivMAb’s unique ability to address previously hard to drug targets in a format ideally suited for antibody discovery."
Vaccinex will present data and examples of successful antibody discovery campaigns against potential oncology targets using the ActivMab Technology at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 29th Annual Meeting held November 8-10, 2024, in Houston, TX.
Meeting SITC 39th Annual Meeting
Date:
Saturday, Nov. 9, 2024
Location: Exhibit Halls A B George R. Brown Convention Center
Poster Title: Discovery of high affinity functional antibodies specific for CXCR5, P2X7 and other multi-pass membrane receptors
Poster Number 1100
Presenter Elizabeth Evans, PhD, Chief Operating Officer, Vaccinex, Inc.
About ActivMAb
ActivMAb is a proprietary antibody discovery platform developed by Vaccinex with unique capabilities for important multi-pass membrane targets such as G-protein-coupled receptors (GPCRs) and ion channels. The ActivMAb technology has multiple applications including discovery of antibodies specific for complex membrane antigens, discovery of antibodies with optimized developability, and protein optimization for expression and activity. Its novel capabilities enable selection of unique antibody drugs against difficult high-value targets, including multi-pass membrane proteins against which small molecule drugs have demonstrated low efficacy or high toxicity. The first clinical candidate selected through use of this technology (CHS-114, a fully human monoclonal antibody targeting CCR8), is in clinical development for cancer immunotherapy by Coherus Biosciences, Inc.